LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Axsome Therapeutics Inc

Closed

SectorHealthcare

103.3 0.69

Overview

Share price change

24h

Current

Min

101.87

Max

106.54

Key metrics

By Trading Economics

Income

15M

-59M

Sales

2.7M

121M

EPS

-1.216

Profit margin

-48.914

Employees

712

EBITDA

14M

-57M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+74.74% upside

Dividends

By Dow Jones

Next Earnings

4 sie 2025

Market Stats

By TradingEconomics

Market Cap

-467M

5B

Previous open

102.61

Previous close

103.3

News Sentiment

By Acuity

50%

50%

162 / 380 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

Axsome Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 cze 2025, 20:51 UTC

Earnings

These Stocks Moved the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 cze 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27 cze 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

27 cze 2025, 20:48 UTC

Market Talk

Computer Lobby Cheers Move to Punish Canada Over Digital Tax -- Market Talk

27 cze 2025, 20:46 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27 cze 2025, 20:46 UTC

Market Talk

Canada Dismissal of Risk From Digital Tax Is 'Shocking' -- Market Talk

27 cze 2025, 19:31 UTC

Market Talk

Canada CEOs Call for Carney to Drop Digital Tax -- Market Talk

27 cze 2025, 19:19 UTC

Market Talk

Oil Posts Weekly Loss As Geopolitical Premium Evaporates -- Market Talk

27 cze 2025, 19:16 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

27 cze 2025, 18:57 UTC

Acquisitions, Mergers, Takeovers

Russian Oligarch Roman Abramovich Is Evraz PLC's Largest Shareholder With 29% Stake -- WSJ

27 cze 2025, 18:57 UTC

Acquisitions, Mergers, Takeovers

Evraz North America Parent Evraz PLC Remains Under Sanction by U.K. -- WSJ

27 cze 2025, 18:57 UTC

Acquisitions, Mergers, Takeovers

Evraz North America Employs About 3,400 People, Has 3.5 Million Tons of Finished Steel Capacity -- WSJ

27 cze 2025, 18:57 UTC

Acquisitions, Mergers, Takeovers

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 cze 2025, 18:57 UTC

Acquisitions, Mergers, Takeovers

Atlas Holdings to Buy Evraz North America for Up to $500 Million, Companies Say -- WSJ

27 cze 2025, 18:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 cze 2025, 18:42 UTC

Market Talk

Canada's Carney 'Likely Amenable' to Dropping Digital-Services Tax -- Market Talk

27 cze 2025, 18:39 UTC

Market Talk
Earnings

Nike's Second-Half Prospects Can Get Better as Worst is Behind it -- Market Talk

27 cze 2025, 18:29 UTC

Market Talk

Canada Recession Risks Likely to Rise With Trump's Termination of Tariff Talks -- Market Talk

27 cze 2025, 18:18 UTC

Market Talk

Canadian Dollar Sharply Weakens on Trump's Surprise End to US-Canada Tariff Talks -- Market Talk

27 cze 2025, 18:16 UTC

Market Talk

Trump's Threat Against Canada Weighs Down Treasurys -- Market Talk

27 cze 2025, 17:16 UTC

Market Talk

U.S. Oil Rig Count Falls by 6 to 432 -- Market Talk

27 cze 2025, 17:08 UTC

Earnings

McDonald's Stock Has Slipped. One Analyst Sees 21% Upside. -- Barrons.com

27 cze 2025, 16:52 UTC

Acquisitions, Mergers, Takeovers

Nike Stock Soars After Earnings. Is It Time to Just Buy It? -- Barrons.com

27 cze 2025, 16:22 UTC

Earnings

These Stocks Are Moving the Most Today: Nike, Nvidia, Coinbase, Palantir, Boeing, Newmont, Core Scientific, and More -- Barrons.com

27 cze 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

27 cze 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

27 cze 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

27 cze 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

27 cze 2025, 15:59 UTC

Market Talk

Gold Futures Slump on Improving Risk Appetite -- Market Talk

27 cze 2025, 15:56 UTC

Market Talk

Nvidia Again Helping To Power New S&P Highs -- Market Talk

Peer Comparison

Price change

Axsome Therapeutics Inc Forecast

Price Target

By TipRanks

74.74% upside

12 Months Forecast

Average 179.23 USD  74.74%

High 210 USD

Low 148 USD

Based on 16 Wall Street analysts offering 12 month price targets forAxsome Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

16

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

107.24 / 112.29Support & Resistance

Short Term

Weak Bearish Evidence

Intermediate Term

Neutral Evidence

Long Term

Strong Bullish Evidence

Sentiment

By Acuity

162 / 380 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Axsome Therapeutics Inc

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.